Trial Profile
Open-Label, Randomised, Parallel Group, Multicentre, Phase III Study To Assess Efficacy, Safety and Tolerability Of Gefitinib (IRESSA) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 May 2019
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPASS
- Sponsors AstraZeneca
- 16 Mar 2019 Results aiming to develop statistical framework to predict PFS and OS in IPASS and IFUM trial (NCT00322452 and NCT01203917)presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 23 Mar 2018 Results (n=1312) assessing the value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer using data of patients those with either EGFR mutation exon 19 deletion or exon 21 L858R mutations from five phase III randomized trials EURTAC, IPASS, ENSURE, LUX-Lung 3 , and LUX-Lung 6, published in the Journal of Thoracic Oncology.
- 06 Jun 2017 Results developing model relating tumor load dynamics to a time evolving hazard of progression using data from this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.